ATE224957T1 - Neue nukleinsaure-polymer komplexe, verfahren zur deren herstellung und verwendung zur transfektion von zellen - Google Patents

Neue nukleinsaure-polymer komplexe, verfahren zur deren herstellung und verwendung zur transfektion von zellen

Info

Publication number
ATE224957T1
ATE224957T1 AT95918049T AT95918049T ATE224957T1 AT E224957 T1 ATE224957 T1 AT E224957T1 AT 95918049 T AT95918049 T AT 95918049T AT 95918049 T AT95918049 T AT 95918049T AT E224957 T1 ATE224957 T1 AT E224957T1
Authority
AT
Austria
Prior art keywords
polymeric conjugate
functions
free
nucleic acid
residues
Prior art date
Application number
AT95918049T
Other languages
English (en)
Inventor
Patrick Midoux
Patrick Erbacher
Annie-Claude Roche-Degremont
Michel Monsigny
Original Assignee
Idm Immuno Designed Molecules
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idm Immuno Designed Molecules filed Critical Idm Immuno Designed Molecules
Application granted granted Critical
Publication of ATE224957T1 publication Critical patent/ATE224957T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT95918049T 1994-04-28 1995-04-24 Neue nukleinsaure-polymer komplexe, verfahren zur deren herstellung und verwendung zur transfektion von zellen ATE224957T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9405174A FR2719316B1 (fr) 1994-04-28 1994-04-28 Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
PCT/FR1995/000535 WO1995030020A1 (fr) 1994-04-28 1995-04-24 Nouveaux complexes d'acide nucleique et de polymere, leur procede de preparation et leur utilisation pour la transfection de cellules

Publications (1)

Publication Number Publication Date
ATE224957T1 true ATE224957T1 (de) 2002-10-15

Family

ID=9462633

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95918049T ATE224957T1 (de) 1994-04-28 1995-04-24 Neue nukleinsaure-polymer komplexe, verfahren zur deren herstellung und verwendung zur transfektion von zellen

Country Status (9)

Country Link
US (1) US5595897A (de)
EP (1) EP0753070B1 (de)
AT (1) ATE224957T1 (de)
AU (1) AU695056B2 (de)
CA (1) CA2187629C (de)
DE (1) DE69528363T2 (de)
ES (1) ES2181775T3 (de)
FR (1) FR2719316B1 (de)
WO (1) WO1995030020A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US5733762A (en) * 1994-04-28 1998-03-31 I.D.M. Immuno-Designed Molecules Complexes of nucleic acid and polymer, their process of preparation and their use for the transfection of cells
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
EP0775751A3 (de) * 1995-11-22 1998-06-10 F. Hoffmann-La Roche Ag Zelltransfektion
CA2256900A1 (en) * 1996-05-29 1997-12-04 Xiao-Ying Meng Cationic polymer/lipid nucleic acid delivery vehicles
US5948681A (en) * 1996-08-14 1999-09-07 Children's Hospital Of Philadelphia Non-viral vehicles for use in gene transfer
EP0839913B1 (de) * 1996-11-04 2006-06-21 Ottawa Health Research Institute Verfahren zur Expression von Polypeptide in Fishen durch wässerung in DNS enthaltende Lösung
FR2755976B1 (fr) * 1996-11-15 1999-01-15 Idm Immuno Designed Molecules Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
EP1054694A2 (de) 1998-02-13 2000-11-29 Selective Genetics, Inc. Gleichzeitige strömungsdurchmischung zur herstellung von zusammensetzungen, die gentherapievektoren enthalten
CA2350882C (en) 1998-11-12 2011-02-22 Life Technologies Corporation Transfection reagents
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
IL131074A0 (en) 1999-07-23 2001-03-19 Polygene Ltd A biodegradable polycation composition for delivery of an anionic macromolecule
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
WO2001036599A1 (en) * 1999-11-19 2001-05-25 Chiron Corporation Microparticle-based transfection and activation of dendritic cells
EP1156832A1 (de) 1999-12-28 2001-11-28 Transgene S.A. Die verwendung von lithium (li+) zur präparation einer zusammensetzung für die transformation eines polynukleotides in eine zelle und zusammensetzungen für die gentherapie
AU2001238485A1 (en) * 2000-02-18 2001-08-27 The Immune Response Corporation Methods and compositions for gene delivery
AU783128B2 (en) 2000-03-02 2005-09-29 Innovata Plc TCF responsive element
AU9066001A (en) * 2000-09-08 2002-03-22 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
US20060094643A1 (en) * 2002-07-03 2006-05-04 Yuri Svirkin Compositions of hyaluronic acid and methods of use
CA2513072A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
AU2004260935A1 (en) * 2003-06-30 2005-02-10 Canji, Inc. Polymer encapsulation of adenoviruses
WO2008036929A2 (en) * 2006-09-21 2008-03-27 Alnylam Pharmaceuticals, Inc. Complex for transferring an anionic substance into a cell
WO2009046833A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
GB0724253D0 (en) 2007-12-12 2008-01-30 Fermentas Uab Transfection reagent
FR2928373B1 (fr) * 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
US9856456B2 (en) 2009-10-12 2018-01-02 Thermo Fisher Scientific Baltics Uab Delivery agent
EP2549859B1 (de) 2010-03-24 2017-06-21 Institut National de la Santé et de la Recherche Médicale Mit einem Hepatitis-B-Virus aus menschlischem Gentotyp Primatenmodell der Familie der Cercopithecidae
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
CN110418650A (zh) 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
EP3612556B8 (de) 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Verbesserte lamp konstrukte
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
EP4061405A1 (de) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Impfstoffe auf der basis von mutantem calr und jak2 und deren verwendungen
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4175664A2 (de) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostata-neoantigene und ihre verwendungen
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
CA3247515A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4104186A1 (de) * 1991-02-12 1992-08-13 Genentech Inc Neue, ueber endozytose in hoehere eukaryotische zellen aufnehmbare, nukleinsaeure enthaltende komplexe

Also Published As

Publication number Publication date
EP0753070A1 (de) 1997-01-15
CA2187629A1 (fr) 1995-11-09
DE69528363T2 (de) 2003-05-15
FR2719316B1 (fr) 1996-05-31
CA2187629C (fr) 2004-09-21
AU2412895A (en) 1995-11-29
FR2719316A1 (fr) 1995-11-03
EP0753070B1 (de) 2002-09-25
AU695056B2 (en) 1998-08-06
WO1995030020A1 (fr) 1995-11-09
ES2181775T3 (es) 2003-03-01
DE69528363D1 (de) 2002-10-31
US5595897A (en) 1997-01-21

Similar Documents

Publication Publication Date Title
DE69528363D1 (de) Neue nukleinsaure-polymer komplexe, verfahren zur deren herstellung und verwendung zur transfektion von zellen
DE60016900T2 (de) Biologische abbaubare und wärmeempfindliche polyphosphazene und verfahren zu ihrer herstellung
US6441089B1 (en) Water-soluble polymers and compositions thereof
Shi et al. Comprehensive characterization of surface-functionalized poly (amidoamine) dendrimers with acetamide, hydroxyl, and carboxyl groups
DE3782394T2 (de) Immobilisiertes, physiologisch aktives material.
BR9205130A (pt) Agente de revestimento aquoso,processo para a producao de um agente,processo de laqueamento e uso
WO2007060119A1 (de) Herstellung und verwendung von hochfunktionellen, hoch- oder hyperverzweigten polylysinen
ATE177124T1 (de) Modifikation von polypropylen durch polyetheramine
CA2111853A1 (en) Substantially pure receptor like tgf-.beta.1 binding molecules and uses thereof
CA2177810A1 (en) Aqueous Branched Polymer Dispersion
AU5123998A (en) Novel polymeric complexes for the transfection of nucleic acids, with residues causing the destabilisation of cell membranes
DE69731205D1 (de) Verbessertes verfahren zur herstellung hochmolekularer polyester
ATE38678T1 (de) Makroporoese perlpolymerisate, verfahren zu ihrer herstellung und ihre anwendung.
BR0009501A (pt) Matéria-prima de revestimento consistindo em pelo menos três componentes, processo para sua preparação assim como seu emprego
BR9610946A (pt) Composição de revestimento compreendendo pelo menos 3 componentes processo para sua preparação e seu uso
DE69412815T2 (de) Künstliche rezeptoren, antikörper und enzyme
BR9611181A (pt) Processo de alumina bayer.
ATE349499T1 (de) Strukturviskose, von organischen lösemitteln und externen emulgatoren freie pulverklarlack-slurry, verfahren zu ihrer herstellung und ihre verwendung
EP0722362A1 (de) Verfahren und träger für die gelpermeationschromotographie
WO2003031062A1 (de) Alkalistabile hydrophile sorbentien für die ionenaustauschchromatographie
DE69633955D1 (de) Stabilisator für chlorhaltige Polymere, Verfahren zu deren Herstellung und chlorhaltige Polymerzusammensetzung
Narayani et al. Collagen-poly (HEMA) hydrogels for the controlled delivery of methotrexate and cisplatin
JPH02229817A (ja) ノニオン性水可溶性ポリマー
EP1054960A1 (de) Heteroaromatische oligoamide als affinitätsliganden
EP0928311B1 (de) Formgegenstand mit reaktiven funktionen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties